In the current study, MALT1 was observed to reduce longitudinally during treatment, whose reduction correlated with RA treatment outcome (treatment response, low disease activity, or disease remission), which was in line with the previous study in IBD patients (14). This evidence concerns the gene MALT1 and inflammatory bowel disease.